EP3498278A1 — Compounds for treatment of diseases related to dux4 expression
Assigned to Facio Intellectual Property BV · Expires 2019-06-19 · 7y expired
What this patent protects
The present invention relates to compounds for the treatment of diseases related to DUX4 expression, such as muscular dystrophies, in this case facioscapulohumeral muscular dystrophy (FSHD). It also relates to use of such compounds, or to methods of use of such compounds.
USPTO Abstract
The present invention relates to compounds for the treatment of diseases related to DUX4 expression, such as muscular dystrophies, in this case facioscapulohumeral muscular dystrophy (FSHD). It also relates to use of such compounds, or to methods of use of such compounds.
Drugs covered by this patent
- Piqray (alpelisib) · Novartis
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.